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Abstract
BACKGROUND: Sacral nerve stimulation (SNS) approved for use in North America since 1997 despite the fact that 
the concept of using SNS to treat patients with voiding dysfunction discussed first almost 50 years ago.
AIM: The objectives of the study were to assess the effectiveness of SNS the short and long term for patients with 
overactive bladder (OAB) dysfunction and its relation to age, gender, and causes.
PATIENTS AND METHODS: This is a clinical prospective study that involved 50 cases (32 females and 18 males) 
with OAB. It was carried out at Ibn Sina Hospital, and the neurosciences hospital in Baghdad/Iraq from April 2015 to 
April 2018. All the patients were assessed preoperatively and certain inclusion criteria were used. The patients went 
through the 2 stage implantations of the Medtronic InterStim®. The patients were assessed at 6 months (short term) 
and 2 years (long term) postoperatively.
RESULTS: The results of our patients were analyzed with respect to age, gender, causes of OAB, and post-operative 
complications. We found that younger age patients, female patients, and patients with neurogenic causes of OAB 
showed a better response in both the short- and long-term follow-up.
CONCLUSION: Considerable progress has been made in the surgical management of OAB. Proper selection of 
patients is the key to the success of SNS, and female patients have better results compared to male patients. 
Furthermore, younger patients and patients with neurogenic causes did better than older patients and patients with 
idiopathic causes. SNS is a safe minimally invasive surgery with a low complication rate, and the 2 stages procedure 
has better results than the percutaneous nerve evaluation.
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Introduction
Before the emergence of neuromodulation, Clare 
Fowler suggested organic etiology for voiding dysfunction 
in patients with signs of secondary neuroendocrine 
abnormalities. However, the patients who were 
complaining of urine retention for many years, regained 
a spontaneous voiding after a simple test of sacral roots 
stimulation. This had led to a major reconsideration of the 
concept of “idiopathic retention” [1], [2].
The results of sacral neuromodulation (SNM) 
were promising in the nineties of the past century. 
However, the absence of long-term improvement for 
some patients led to the questioning of the indications 
and effectiveness of SNM.
Neurogenic dysfunction is now looked upon 
as a complex combination of functional abnormalities. 
Many of these dysfunctions which were considered as 
“idiopathic” are dealt with now as “non-overt neurogenic.” 
Combinations of pelvic organ dysfunctions, including 
constipation, voiding dysfunction, sexual dysfunction, 
urinary retention, fecal incontinence, and/or urinary 
incontinence, improve with the same treatment modality. 
This has led to the realization that the effects of SNM 
are localized in dealing with sacral symptoms [3].
At least three large randomized controlled trials 
confirmed the efficacy of implanted sacral neuromodulator 
for the treatment of patients suffering from severe urgency 
and urged urinary incontinence. In previous researches, 
large variation in the clinical profiles, the severity of 
symptoms, and treatments received before implantation 
of the implantation of sacral neuromodulator [3].
One of the surgical options for the treatment 
of bladder dysfunctions involves the implantation of a 
small device that acts in a way that resembles the action 
of the pacemaker of the heart in some way. Medtronic 
developed “InterStim® therapy” which is a method of 
SNS. This device was approved for use in the United 
States by the Food and Drug Administration in 1997 [4].
OAB is defined as urinary urgency, usually 
with urinary frequency and nocturia, with or without 
urgency urinary incontinence (UUI) [5], [6], [7]. UUI 
affects more than forty percent of patients with OAB [8]. 
Whereas among all patients with urinary incontinence 
about 40–70% are due to OAB. Most patients with this 
condition have it for years [9], [10].
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Aims of the study
The aim of the study was to assess the short- 
and long-term effectiveness of SNS in patients with 
overactive bladder (OAB) regarding age, gender, and 
causes.
Patients and Method
This is a clinical prospective cohort study 
conducted between April 2015 and April 2018 in 
Ibn Sina hospital and the neurosciences hospital in 
Baghdad/Iraq. Fifty patients were included in the study, 
32 females and 18 males. The age distribution of the 
patients ranged from 17 to 45 years and patients were 
divided into two age groups: First group ages from 17 to 
30 years and second group ages from 31 to 45 years. 
All the patients had undergone complete investigations 
for treatable urological problems, neurological diseases 
and had been evaluated by a team of neurosurgeons 
and urologists to evaluate and assess them. Consents 
were taken from all the patients or their relatives after 
explaining the surgical technique and the expected 
outcome and the possible complications for them.
The patients were reevaluated at 6 months 
postoperatively, as a short-term response follow-up, 
and 2 years postoperatively as the long-term response 
follow-up.
Patients inclusion criteria for the current 
study were
1. Failure to respond to conservative treatment 
for more than 3 months
2. No concomitant comorbidities
3. Good mentality and intellectual capabilities 
and cooperation
4. Strict to follow-up periods
5. No treatable causes (urological nor 
neurological)
6. No urinary outlet obstruction
7. Female patients should not be pregnant
8. Well and healthy site of implantation
9. Succeeded in the temporary phase.
The exclusion criteria were as follows
1. Pre-pubertal
2. Mixed incontinence (with stress component 
more than the urge one)
3. Bladder outlet obstruction
4. Agenesis of the sacrum
5. Failure of follow-up
6. Failure to proceed to the permanent phase
7. Pregnant females.
The first step in the patient’s management 
algorithm is that the patient should fill a voiding diary to 
serve as a baseline record of the patient’s clinical response. 
This is followed by the evaluation of the team. If the team 
decided to do surgery, the patient would be informed about 
the successive steps and formal consent was to be filled. 
Using the Medtronic-InterStim® kit, the procedure then 
starts by implanting the temporary lead and external pulse 
generator (EPG). The patient should be in a prone position. 
The patient was then prepared and draped, exposing both 
feet and perineum to observe the signs of response on 
stimulation. Landmarks were set with or without the help 
of the C-arm. Skin marking and infiltration with local 
anesthetics solution was followed by insertion of a size 
20G, 3.5-inch insulated needle into the S3 foramen on 
both sides in a vertical orientation in relation to the skin and 
under the guidance of fluoroscopy to ensure the location 
and depth of the inserted needle. Electrical stimulation was 
then applied through the needle to confirm the position of 
the needle by the observation of gluteal contraction, pelvic 
floor contraction, with plantiflexion of the big toe. In addition, 
the awake patient can report a tingling sensation of the 
pelvic floor. Plantiflexion of the foot with lateral rotation 
indicates the insertion of the needle in S2 foramen. On the 
other hand, the absence of lower extremity movement 
indicates insertion in the S4 foramen. After confirmation 
of the correct position of the needle, temporary lead wire 
inserted through the needle before careful removal of the 
needle to avoid inadvertent dislodgment of the lead. The 
temporary leads then fixed to the skin by steri-strips and a 
sterile dressing applied.
The patient then discharged with EPG. The 
temporary leads could be left for up to 2 months 
according to the patient’s maximum response while the 
patient completed voiding diaries.
On follow-up period, records were compared 
and patients were designed as good responders if 
≥50% improvement of their complaints. Those would be 
later candidates for permanent internal pulse generator 
(IPG) implantation which would be done in the operating 
room. The patient took the same prone position and the 
lead was connected to the embedded IPG.
The outcome was assessed according to the 
following parameters: 
1. Number episodes of incontinence in 24 h
2. Number of diapers change in 24 h
3. Severity of incontinence
4. Day-time frequency
5. Nocturnal frequency.
According to the above parameters, the patients 
were assessed in the short term (6 months) and long 
term (2 years) in accordance with these parameters 
and classified as: worse (the episodes or amount of 
incontinence increase or the frequency increases), no 
change (no change or the improvement is <50%), good 
improvement (the episodes and amount of incontinence 
are <½ half the baseline or if the time between micturition 
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is double or more), or very good improvement (when 
there is full control and the frequency of micturition is <8 
in a day-time and <2 in sleeping time).
The study was approved by the scientific and 
ethical committee in Al-Kindy College of Medicine – 
University of Baghdad.
Statistical analysis
Descriptive analysis in the form of percentage 
was calculated using Microsoft Office Excel Worksheet 
and presented in the relevant tables shown below. Chi-
square test was used for statistical analysis by utilizing the 
Statistical Package for the Social Sciences (SPSS) version 
17(p < 0.05 was considered statistically significant).
Results
Among the 68 initial candidates for the 
implantation of the sacral neuromodulator, 50 patients 
were included in this study (32 female and 18 male) and 
18 patients were excluded. Of the excluded patients, 
3 patients were pre-pubertal, 6 patients had mixed 
urinary incontinence with associated internal sphincter 
deficiency on the urodynamic study, 2 patients refused 
an operative intervention, 2 patients had uncontrolled 
diabetes, 2 patients had evidence of bladder outflow 
obstruction, 1 patient had a positive pregnancy test, 
and 2 patients were missed from the follow-up.
The results of the age and gender distribution 
are shown in Table 1.
Table 1: Age and gender distribution of the patients
Age group Female 
number (%)
Male 
number (%)
Total number 
(%)
1st age group (17–30 years) 15 (30) 10 (20) 25 (50)
2nd age group (31–45 years) 17 (34) 8 (16) 25 (50)
 At baseline, there was no significant difference 
between the two age groups and no difference 
between males and females regarding the frequency of 
micturition and the number of episodes of incontinence.
On the short- and long-term follow-up, there 
was no worsening or no change in the condition of our 
patients.
In female patients, there was a statistically 
significant better outcome in Group 1 compared to 
Group 2 (p = 0.001), both on short- and long-term 
follow-up. The same was found in male patients, 
p = 0.001 (Table 2).
Overall, the female patients had better 
outcomes compared to male patients in the long-term 
follow-up (p = 0.01).
The causes of OAB were idiopathic in 11 
(22%) patients and neurogenic in 39 (78%) patients. 
The neurogenic causes were due to: Spinal cord injury 
n = 12 (24%), multiple sclerosis n = 7 (14%), spinal 
dysraphism n = 6 (12%), failed back surgery syndrome 
n = 10 (20%), and other causes n = 4 (8%).
Table 2: Short- and long-term assessment according to age 
and gender
Age and gender follow-up Worse No 
change
Good 
improvement
Very good 
improvement
Female (17–30 years) n = 15 6 months 0 0 5 10
Female (17–30 years) n = 15 2 years 0 0 1 14
Female (31–45 years) n = 17 6 months 0 0 12 5
Female (31–45 years) n = 17 2 years 0 0 11 6
Male (17–30 years) n = 10 6 months 0 0 6 4
Male (17–30 years) n = 10 2 years 0 0 4 6
Male (31–45 years) n = 8 6 months 0 0 7 1
Male (31–45 years) n = 8 2 years 0 0 6 2
There was a better outcome in patients with 
neurogenic causes compared to those with idiopathic 
causes, which was statistically significant, both on 
short-term (p = 0.01) and long-term (p = 0.005) follow-up 
(Table 3).
Table 3: Short- and long-term assessment according to the 
cause of overactive bladder
Causes Worse No 
change
Good 
improvement
Very good 
improvement
Idiopathic n = 11 6 months 0 0 11 0
Idiopathic n = 11 2 years 0 0 10 1
Neurogenic n = 39
Spinal cord injury n = 12 0 0 7 5
MS n = 7 0 0 3 4
Spinal dysraphism n = 6 0 0 3 3
Failed back surgery syndrome n = 10 0 0 4 6
Others n = 4 6 months 0 0 2 2
Neurogenic n = 39
Spinal cord injury n = 12 0 0 4 8
MS n = 7 0 0 2 5
Spinal dysraphism n = 6 0 0 2 4
Failed back surgery syndrome n = 10 0 0 2 8
Others n = 4 2 years 0 0 2 2
Post-operative complications during the 
follow-up period are listed in Table 4.
Table 4: Post-operative complications on short- and long-term 
follow-up
Complications Short-term number (%) Long-term number (%)
Pain at the site of implant 22 (44) 1 (2)
Infection 4 (8) 0
Electrode movement 1 (2) 0
Uncomfortable stimulation (sometimes 
described as shocking sensation)
6(12) 2 (4)
Pain at the site of implantation was treated with 
simple analgesia, the infection was treated with meticulous 
dressing and antibiotics, electrode movement was 
treated by surgical repositioning of the electrode, and the 
uncomfortable stimulation was tolerable by the patients.
Discussion
Overall the female patients had better 
outcomes compared the male patients. The younger 
age group had a better outcome and the neurogenic 
cause of OAB also showed better results.
A proportion of patients with OAB improved on 
standard medical therapy. The main medical treatment 
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depends on anticholinergic drugs which reduce the 
contractility of the bladder muscle (the efferent limb 
of micturition reflex). Some patients may not respond 
well to anticholinergic medications. In addition, more 
than two-thirds of the patients are reluctant to use the 
medications in the long term due to its side effects 
or due to incomplete relief of the symptoms. While 
anticholinergic drugs act at the level of the detrusor 
muscle, SNM acts at the level of the nerve supply of 
the bladder to modulate the connection between the 
bladder and the higher centers controlling the storage-
voiding function of the bladder [11].
In this study, female patients did better than 
male patients, presumably because the number of 
female patients with OAB was more than the male 
patients. In addition, the anatomy of the female bladder 
is less complicated than male bladder and urethra.
Mehmood and Altaweel found that: SNM has 
demonstrated high rates of clinical success, a significant 
reduction in voiding-related symptoms, voided volume, 
and the number of diapers used daily. They also noticed 
a better female response in the long-term follow-up and 
neurogenic underlying causes [12]. These are similar 
to our results.
We also found that the younger age group 
showed better results and earlier than the older 
patients. The cause may be due to the unsettlement 
of the pathological changes as compared to the older 
patients. This is probably partly due to the shorter 
duration of the disease at the time of presentation, that 
is, the severity of the changes can be less, and thus 
their near-normal anatomy.
Similar long-term data were obtained by  Elhilali 
et al. [3], [4] and Van Voskuilen et al. [13]. 
White et al. also found that, at a mean follow-up 
of 40 months, 85.7% of patients demonstrated a >50% 
improvement in symptoms with SNM and its better in 
younger patients [10], [14].
Although both patients with neurogenic and 
idiopathic causes of OAB did improve after the surgery, 
the neurogenic group showed better responses in both 
short- and long-term follow-up. This may be explained 
by the fact that knowing the underlying cause will lead 
to treating it accordingly, unlike the idiopathic causes 
that were of unspecified nature.
All our patients underwent the 2 stages 
technique of SNM. Everaert et al. found that the 2 
stages implantation for SNM has a higher success rate 
than the 1-stage implantation [15], [16].
Datta et al. found that the 2 stages procedure 
is better than the percutaneous nerve evaluation (PNE) 
in the restoration of voiding. They further elaborated 
that of the eight patients with negative PNE results, 
when they proceeded to the 2 stages procedure, five 
had voiding restored [13], [17].
Conclusion
Proper selection of patients is the key to the 
success of SNS. This study concluded that female 
patients have better results compared to male patients. 
Furthermore, younger patients and patients with 
neurogenic causes did better than older patients and 
patients with idiopathic causes. Overall, the 2 stages 
SNS procedure is a safe minimally invasive procedure 
with a low complication rate.
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